Form 8-K - Current report:
SEC Accession No. 0001193125-24-246535
Filing Date
2024-10-29
Accepted
2024-10-29 16:10:01
Documents
15
Period of Report
2024-10-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d856425d8k.htm   iXBRL 8-K 24492
2 EX-99.1 d856425dex991.htm EX-99.1 75747
6 GRAPHIC g856425g99l88.jpg GRAPHIC 2137
  Complete submission text file 0001193125-24-246535.txt   237087

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20241029.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20241029_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20241029_pre.xml EX-101.PRE 10811
18 EXTRACTED XBRL INSTANCE DOCUMENT d856425d8k_htm.xml XML 3555
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 241405795
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)